Clostridium difficile Infection

Infect Dis Clin North Am. 2017 Sep;31(3):489-495. doi: 10.1016/j.idc.2017.05.012.

Abstract

Clostridium difficile infection is a major health care challenge in terms of patient and economic consequences. For the patient, it is a morbid and sometimes a life-threatening iatrogenic complication of antibiotic treatment. In the United States, the provider's institution may face financial penalties, because the Centers for Disease Control and Prevention views this as an iatrogenic health care-associated complication that may not be reimbursable by the Centers for Medicare and Medicaid Services; this has resulted in substantial incentives for new approaches to prevention and treatment.

Keywords: Centers for Disease Control and Prevention; Clostridium difficile; Intensive care units; White blood cell.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use
  • Centers for Disease Control and Prevention, U.S.
  • Clostridioides difficile / isolation & purification*
  • Clostridium Infections / diagnosis
  • Clostridium Infections / microbiology
  • Clostridium Infections / prevention & control*
  • Clostridium Infections / therapy*
  • Cross Infection / diagnosis
  • Cross Infection / microbiology
  • Cross Infection / therapy
  • Diarrhea / microbiology
  • Diarrhea / therapy
  • Fecal Microbiota Transplantation
  • Humans
  • Iatrogenic Disease
  • Intensive Care Units
  • Risk Factors
  • United States / epidemiology

Substances

  • Anti-Bacterial Agents